1. Introduction {#sec0005}
===============

Reverse epidemiology of preexisting hypertension at admission with all-cause mortality within 5-years follow-up in patients with systolic heart failure (HF) has been well known in the Western world.[@bib0005] However, this finding was not consistent across researches performed in the Asian countries. For instance, Lee et al have shown that systolic blood pressure rather than preexisting hypertension were associated with mortality in a Korean cohort with systolic HF.[@bib0010] Whether these conflicting results came from ethnical difference or the moderator such as age and obesity was unknown. Therefore we investigated the association between preexisting hypertension and the mortality in a large sample of patients with systolic HF in Taiwan.

2. Methods {#sec0010}
==========

The Taiwan Society of Cardiology-Heart Failure with Reduced Ejection Fraction *(TSOC-HFrEF)* registry was a multicenter study aimed to prospectively investigate the prognosis of patients with systolic HF in Taiwan from May, 2013 to October, 2015. The study design for TSOC-HFrEF has been published elsewhere.[@bib0015], [@bib0020] In brief, the registry included 1509 patients admitted for acute worsening HF, whose echocardiographic left ventricular ejection fraction was less than 40%. Preexisting hypertension was defined as a history of systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg ever recorded, or the use of antihypertensive medications prior to this study. We excluded those with missing data on relevant variables, leaving a sample of 1351 (93.2%) for analysis. Outcomes of interest were 1) all-cause mortality, 2) cardiovascular mortality, defined as death of sudden cardiac death, ischemic heart disease, stroke, refractory HF, and lethal arrhythmia, and 3) non-cardiovascular mortality. The analysis used the time for follow-up at the patients' first enrollment (May, 2013--October, 2014) with censoring at the occurrence of mortality, or end of follow-up (October 31, 2015). The origin and the issue date of mortality were verified according to the medical record. The jointed ethics committee has approved the protocol and that informed consent has been obtained from the subjects. Cox proportional hazard regression analyses were used to assess the multivariable association of preexisting hypertension with mortality, adjusting for potential confounders at baseline including age, sex, body mass index, old myocardial infarction, diabetes, dyslipidemia, current smoking status, current alcohol intake, chronic obstructive pulmonary disease, New York Heart Association function class, and medications. These covariates for the adjustments were chosen based on prior published data related to HF mortality.[@bib0015], [@bib0020] Stratified analyses exploring the association between preexisting hypertension and the mortality within age \<65 (n = 693) and ≥65 (n = 658) years, and a formal test for interaction between these two age groups were performed. A 2-tailed value of p \< 0.05 was considered significant. All statistical analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC).

3. Results {#sec0015}
==========

[Table 1](#tbl0005){ref-type="table"} shows the baseline characteristics of participants younger and those older than 65 years of age. There were 293 (42.3%) and 259 (39.4%) hypertensives in the younger and the older groups. As compared with the younger ones, the elderly with HF had more proportion of female sex, ischemic origin, diabetes mellitus, chronic pulmonary disease, and presented worse kidney function and clinical symptoms.Table 1Baseline Characteristics of Patients with Systolic Heart Failure By Age Group.Table 1Age GroupAge \<65 yearsAge ≥65 yearsP-valueN = 693N = 658Hypertension293 (42.3)259 (39.4)0.45Demographic Age, years53.2 ± 10.679.9 ± 7.3\<0.001 Sex (male), %82.962.0\<0.001 Current smoker, %35.111.2\<0.001 Current alcoholic, %21.312.1\<0.001Cause of heart failure, %\<0.001 Ischemic39.854.4 Dilated cardiomyopathy43.723.9 Hypertensive7.38.6 Valvular9.213.1Comorbidities, % Diabetes41.347.80.016 Dyslipidemia25.320.80.05 COPD4.616.9\<0.001 Prior MI20.130.0\<0.001Procedures, %\<0.001 PCI19.610.1 CABG7.831.1 Valvular surgery3.75.5 CIED3.73.8Vital signs at discharge NYHA functional class2.0 ± 0.72.3 ± 0.7\<0.001 Cardiogenic shock%2.72.30.63 In-hospital mortality%1.11.70.39 Heart rate, beats/min81.9 ± 14.878.2 ± 14.6\<0.001 SBP, mmHg118.8 ± 19.6120.6 ± 17.80.09 DBP, mmHg75.7 ± 13.168.7 ± 12.7\<0.001Laboratory data at discharge eGFR, ml min^−1^ 1.73m[@bib0010]65.4 ± 41.047.7 ± 28.4\<0.001 Hemoglobin, g/dl11.5 ± 2.112.2 ± 6.60.21Echocardiographic parameters at discharge LVEDD, mm63.3 ± 14.961.9 ± 27.00.22 LVSDD, mm53.9 ± 12.850.7 ± 19.4\<0.001 LVEF, %26.6 ± 8.329.5 ± 8.6\<0.001Medication use at discharge, % ACE inhibitors32.221.8\<0.001 ARBs35.932.8\<0.001 Beta-blockers65.953.3\<0.001Calcium-channel blockers12.212.70.79 Nitrates31.440.4\<0.001 Digitalis31.420.5\<0.001 Diuretics84.980.10.019 Anti-platelets56.664.20.005 Anti-coagulants22.220.50.45 Anti-arrhythmic agents16.614.60.29[^1]

[Table 2](#tbl0010){ref-type="table"} shows the associations of preexisting hypertension with all-cause mortality, cardiovascular mortality, and non-cardiovascular mortality in the overall cohort (hazard ratios (HR): 0.62, 0.47, and 0.98, respectively) during an average 12 months (range: 8 months--18 months) follow-up period. Similarly, the associations of preexisting hypertension with the mortalities in patients ages less than 65 years were compatible with that in the overall cohort (HR: 0.61, 0.44, 1.25, respectively). After adjustment for all potential risk factors, the associations of preexisting hypertension with all-cause and cardiovascular mortality were reduced in the overall cohort (0.77, 0.53, and 1.41 respectively), and those aged less than 65 years (0.59, 0.28, and 2.05 respectively). Notably, preexisting hypertension was only inversely associated with cardiovascular mortality. By contrast, the associations of preexisting hypertension with the mortality were nonsignificant in the patients ages older than 65 years. There were differences between the risk of cardiovascular and non-cardiovascular mortality in the overall cohort and the patients aged younger than 65 years (p for interaction \<0.05).Table 2Association between preexisting hypertension at admission and the mortality stratified by age in patients with systolic heart failure, 2013--2015.Table 2The overall cohort (n = 1351)Age \<65 years (n = 693)Age ≥65 years (n = 658)All-cause mortalityCrude0.77 (0.54--1.09)0.59 (0.32--1.07)0.91 (0.37--1.40)Adjustment0.77 (0.54--1.09)0.59 (0.32--1.07)0.91 (0.37--1.40)CV mortalityCrude0.53 (0.33--0.84)^\*,§^0.28 (0.11--0.67)^\*,§^0.76 (0.46--1.26)Adjustment0.53 (0.33--0.84)^\*,§^0.28 (0.11--0.67)^\*,§^0.76 (0.46--1.26)Non-CV mortalityCrude1.41 (0.82--2.41)2.05 (0.79--5.36)1.22 (0.66--2.28)Adjustment1.41 (0.82--2.41)2.05 (0.79--5.36)1.22 (0.66--2.28)[^2][^3][^4][^5]

Table 3 shows the results of the associations between each medication use and mortality. We found that merely beta-blockers use was associated with lower risk of all-cause and cardiovascular mortality in the elderly patients with HF (0.61 and 0.58, respectively).

4. Discussion {#sec0020}
=============

Our principal finding in Taiwan showed that preexisting hypertension was not associated with 1-year all-cause mortality in patients with systolic HF. However, there was an inverse association of preexisting hypertension with cardiovascular mortality.

In previous findings from TSOC-HFrEF and the eastern Taiwan integrated health care delivery system of Coronary Heart Disease (ET-CHD) registry,[@bib0020], [@bib0025] we have shown that the obesity paradox phenomenon was present in patients with established cardiovascular disease, particularly in the elderly patients. In addition, several studies also have identified that elevated blood pressure was associated with greater survival in patients with HF.[@bib0005], [@bib0030] These findings might suggest that increased body weight and blood pressure reflect the status of better circulatory power, a strong predictor of survival in systolic HF.[@bib0035], [@bib0040]

Our findings were consistent to the Korean study results by Lee et al that pre- existing hypertension was not associated with all-cause mortality.[@bib0010] In contrast, the reverse epidemiology was only present in patients younger than 65 years of age. This was probably due to a higher prevalence of comorbidities in the elderly HF patients that reduced the effect of some protective factors such as elevated blood pressure on mortality. In addition, beta-blockers which could inhibit sympathetic nervous activation to decrease blood pressure levels had remarkable protective effect on mortality in merely the elderly HF patients, indicating that the benefits and hazards of hypertension may be neutralized in this setting.

The strengths of our study were that the *TSOC-HFrEF* registry was conducted strictly in a nationwide spectrum and prospectively followed up the mortality events. The limitation of our study included that blood pressure levels were not adjusted at baseline for a high correlation with preexisting hypertension that could not be compared with previous study results.

In conclusion, an inverse relationship between preexisting hypertension and cardiovascular mortality was observed in the Asian patients with systolic HF, particularly for younger individuals.

Funding {#sec0025}
=======

The TSOC-HFrEF registry was sponsored by Heart Failure Committee of the TSOC.

Disclosures {#sec0030}
===========

The authors have no conflicts of interest to disclose.

The authors assume full responsibility for the accuracy and completeness of the ideas presented. We also express our gratitude and appreciation to the physicians and nurses participating in the TSOC-HFrEF registry.

[^1]: Abbreviations: COPD, chronic obstructive pulmonary disease; MI, myocardial infarction, TIA, transient ischemic accident; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CIED, cardiac implantable electronic devices; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LV, left ventricular; EDD, end-diastolic diameter; ESD, end-systolic diameter; EF, ejection fraction; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.

[^2]: Cox regression model was used in the analysis adjusting for the covariates including age, sex, history of prior myocardial infarction, body mass index, diabetes, dyslipidemia, current smoking status, current alcohol intake, chronic obstructive pulmonary disease, NYHA functional class, and medications with angiotensin-II receptor blockers, beta-blockers, loop diuretics, spironolactone, anti-platelet agents (aspirin or clopidogrel), and anti-coagulation agents (warfarin or dabigatran).

[^3]: Data was presented as hazard ratio (95% confidence interval).

[^4]: ^\*^P-value \< 0.05.

[^5]: ^§^P for interaction of cause of mortality \<0.05.
